香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司董 事和高級管理人員持股變動管理辦法》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年8月22日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公司 之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 * 僅供識別 上海昊海生物科技股份有限公司 董事和高级管理人 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 2025 年度"提质增效重回报"行动方案的半年度评估报告 为延续 2024 年度行动方案之成果，进一步提高公司质量，助力信心提振、 资本市场稳定和经济高质量发展，公司制定了《上海昊海生物科技股份有限公 司 2025 年度"提质增效重回报"行动方案》（以下简称"《行动方案》"）， 该方案于 2025 年 3 月 21 日经公司第五届董事会第三十次会议审议通过。2025 年上半年，公司贯彻落实《行动方案》的主要举措及成效情况如下： 一、聚焦主营业务持续稳定发展 茲載列本公司在上 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司 2025年半年度募集資金存放與實際使用情況的專項報告》，僅供參考。 承董事會命 上海昊海生物科技股份有限公司 主席 侯永泰 中國上海，2025年8月22日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公司 之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 * 僅供識別 证券代码：688366 证券 ...

Group 1 - The core viewpoint of the articles highlights the financial performance of Haohai Biological Technology for the first half of 2025, showing a decline in revenue and profit compared to the previous year [1][3] - The company's revenue for the reporting period was approximately RMB 1.293 billion, representing a year-on-year decrease of about 7.48% [1] - The profit attributable to ordinary shareholders was approximately RMB 211 million, down about 10.29% from the same period in 2024, with basic earnings per share at RMB 0.91 and an interim dividend of RMB 0.40 per share [1] Group 2 - The company faced challenges due to the implementation of national centralized procurement policies and a sluggish domestic consumption market, leading to a significant decline in the ophthalmology product line revenue, which decreased by approximately RMB 83.51 million, or 18.57% year-on-year [1] - The revenue from the medical beauty and wound care product line also saw a decline of approximately RMB 58.55 million, or 9.27%, primarily due to a temporary decrease in domestic demand for the first and second generation hyaluronic acid products [1] - Conversely, the revenue from the anti-adhesion and hemostatic product line increased by approximately RMB 41.10 million, or 59.68%, mainly due to the inclusion of the "Kangrui Gel" product in the Shanghai Municipal Biopharmaceutical "New and Excellent Drug and Medical Device" product catalog [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：6826） 中國上海，2025年8月22日 於本公告日期，本公司之執行董事為侯永泰博士、吳劍英先生、陳奕奕女士及唐 敏捷先生；本公司之非執行董事為游捷女士、黃明先生及魏長征先生；及本公司 之獨立非執行董事為沈紅波先生、姜志宏先生、蘇治先生及楊玉社先生。 * 僅供識別 证券代码：688366 证券简称：昊海生科 公告编号：2025-039 海外監管公告 本公告乃由上海昊海生物科技股份有限公司（「本公司」）根據《香港聯合交易所有 限公司證券上市規則》第13.10B條的規定刊發。 茲載列本公司在上海證券交易所網站刊登之《上海昊海生物科技股份有限公司 2025年半年度利潤分配方案公告》，僅供參考。 承董事會命 上海昊海生物科技股份 ...

报告期内，该集团紧密围绕医美、眼科、骨科、防黏连及止血四大核心业务板块，积极应对外部环境的 机遇与挑战，持续深化产品创新、市场拓展和精益管理，集团整体经营继续保持了稳健发展态势。报告 期内，受到国家集采政策逐步落地实施以及国内消费市场出现疲态等因素影响，集团眼科产品线整体收 入较2024年同期下降约人民币8351万元，降幅约18.57%。报告期内，集团医疗美容与创面护理产品线 的收入较2024年同期下降约人民币5855万元，降幅约9.27%，主要是集团第一代和第二代玻尿酸产品受 到国内消费需求阶段性减少的影响，收入下降较为明显。 另外，根据国家税务总局《关于生物製品适用增值税政策执行口径》的要求，下属子公司上海其胜所生 产的相关产品不再被认定为适用增值税简易办法徵收率计算的生物制品，增值税率由3%调整为13%， 由于集团无法通过调整含税销售价格的方式消化上述税率调整的影响，导致报告期内相关上海其胜产品 的扣税后销售单价及收入有所下降。报告期内，集团防黏连及止血产品线收入较2024年同期增长约人民 币4110万元，增幅约59.68%，主要是集团"康瑞胶"产品于2024年12月被纳入《上海市生物医药"新优药 械" ...

EF001 免責聲明 | 公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 | 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因 | | | --- | --- | --- | | 股票發行人現金股息公告 | | | | 發行人名稱 | 上海昊海生物科技股份有限公司 | | | 股份代號 | 06826 | | | 多櫃檯股份代號及貨幣 | 不適用 | | | 相關股份代號及名稱 | 不適用 | | | 公告標題 | 截至2025年6月30日止六個月期間之中期業績公告 | | | 公告日期 | 2025年8月22日 | | | 公告狀態 | 新公告 | | | 股息信息 | | | | 股息類型 | 中期（半年期） | | | 股息性質 | 普通股息 | | | 財政年末 | 2025年12月31日 | | | 宣派股息的報告期末 | 2025年6月30日 | | | 宣派股息 | 每 股 0.4 RMB | | | 股東批准日期 | 不適用 | | | 香港過戶登記處相關信息 | | | | 派息金額及 ...

Core Viewpoint - The company reported a decline in revenue and profit for the first half of 2025, attributed to external market challenges and regulatory changes affecting product pricing and demand [1][2]. Financial Performance - The company recorded a total revenue of approximately RMB 1.293 billion, a year-on-year decrease of about 7.48% [1]. - Research and development expenses amounted to approximately RMB 98.4 million, down about 21.53% year-on-year, representing 7.61% of total revenue [1]. - Profit attributable to ordinary shareholders was approximately RMB 211 million, a decline of about 10.29% year-on-year, with basic earnings per share at RMB 0.91 [1]. Business Segments - The company focuses on four core business segments: medical aesthetics, ophthalmology, orthopedics, and anti-adhesion & hemostasis, and has been actively responding to market opportunities and challenges [2]. - Revenue from the ophthalmology product line decreased by approximately RMB 83.51 million, a decline of about 18.57% compared to the same period in 2024, influenced by national procurement policies and a sluggish domestic consumption market [2]. - Revenue from the medical aesthetics and wound care product line fell by approximately RMB 58.55 million, a decrease of about 9.27%, primarily due to reduced domestic demand for the first and second generation hyaluronic acid products [2]. Product Innovations and Market Developments - The anti-adhesion and hemostasis product line saw revenue growth of approximately RMB 41.1 million, an increase of about 59.68%, mainly due to the inclusion of the "Kangrui Gel" product in the Shanghai biopharmaceutical "New and Excellent Drug and Device" product directory [3]. - The inclusion in the directory allows the product to access a green channel for public hospital admission in Shanghai and prioritize recommendations for Shanghai medical insurance negotiations, enhancing market access and patient willingness to pay [3].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 Shanghai Haohai Biological Technology Co., Ltd.* 上海昊海生物科技股份有限公司 為釐定有權獲得中期股息的H股股東名單，本公司將於2025年9月9日（星期二）至 2025年9月12日（星期五）止（包括首尾兩天）期間暫停辦理股份過戶登記手續，該 期間將不辦理H股過戶手續。凡於2025年9月12日（星期五）名列本公司股東名冊 的H股股東均有權收取中期股息。為接獲中期股息，尚未登記其過戶的H股股東應 於2025年9月8日（星期一）下午4:30或之前，將過戶文件連同相關股票送呈至H股 證券登記處，其地址為香港灣仔皇后大道東183號合和中心17樓1712-1716號舖。 茲提述上海昊海生物科技股份有限公司（「本公司」）日期為2025年5月9日的2024 年度股東周年大會（「股東周年大會」）通函（「通函」）及日期為2025年6月10日的公 告，內容有關（其中包括）本公司 ...

Financial Performance - The company recorded revenue of approximately RMB 1,292.64 million for the six months ended June 30, 2025, a decrease of about RMB 104.47 million or 7.48% compared to RMB 1,397.11 million in the same period of 2024[2]. - Profit attributable to equity holders of the company was approximately RMB 211.07 million, a decline of 10.29% from RMB 235.28 million in the same period of 2024[2][6]. - Basic earnings per share for the period were RMB 0.91, compared to RMB 1.01 in 2024[2][6]. - Gross profit for the period was RMB 906.28 million, down from RMB 983.30 million in 2024, reflecting a decrease in gross margin[4]. - Total comprehensive income for the period was RMB 251.81 million, compared to RMB 196.74 million in 2024, indicating an increase in overall profitability[6]. - The group's profit before tax for the six months ended June 30, 2025, was RMB 211,065,000, a decrease of 10.3% compared to RMB 235,283,000 for the same period in 2024[33]. - The total tax expense for the period was RMB 33,965,000, a decrease of 24.4% compared to RMB 44,834,000 for the same period in 2024[28]. - The overall gross profit margin for the reporting period was 70.11%, remaining stable compared to 70.38% in the same period of 2024[82]. Research and Development - Research and development expenses amounted to approximately RMB 98.40 million, down by RMB 27.00 million or 21.53% from RMB 125.40 million in 2024, representing 7.61% of revenue[2][4]. - The company received government subsidies amounting to RMB 7,907,000 for R&D activities, an increase from RMB 6,963,000 in 2024[23]. - Research and development costs for the six months ended June 30, 2025, were RMB 98,401,000, down 21.5% from RMB 125,400,000 in 2024[24]. - The group has several key R&D projects progressing, including the registration phase for multiple new products expected to enhance future revenue streams[46]. - The group will promote high-end hyaluronic acid products and continue clinical trials for important R&D projects, including painless cross-linked hyaluronic acid[77]. Assets and Liabilities - Non-current assets totaled RMB 3,483.08 million as of June 30, 2025, slightly up from RMB 3,463.12 million at the end of 2024[7]. - Current assets increased to RMB 3,702.72 million from RMB 3,658.27 million at the end of 2024, driven by higher trade receivables and cash balances[8]. - The company's total equity was RMB 5,882.26 million, a slight decrease from RMB 5,917.04 million at the end of 2024[8]. - The total liabilities as of June 30, 2025, were approximately RMB 1,303.54 million, with a debt-to-asset ratio of 18.14%, an increase of 1.23 percentage points from 16.91% on December 31, 2024[92]. - Cash and cash equivalents as of June 30, 2025, were approximately RMB 614.29 million, a decrease of about RMB 498.62 million compared to RMB 1,112.91 million on December 31, 2024[93]. Share Repurchase and Dividends - The company repurchased a total of 12,938,800 H-shares from March 2020 to December 2024, with 12,742,900 shares canceled by December 31, 2024[10]. - For A-shares, the company completed the first round of repurchases totaling 2,015,674 shares from August 2023 to August 2024, followed by a second round of 1,832,421 shares from November 2024 to June 2025[11]. - The board declared an interim dividend of RMB 0.40 per share (tax inclusive), unchanged from the same period in 2024[2]. - The board approved an interim dividend of RMB 0.40 per share (tax included), amounting to a total of RMB 91,493,200.00 (tax included) based on 232,581,095 shares issued[103]. Market Performance - Revenue from customer contracts for the six months ended June 30, 2025, was RMB 1,292,636,000, a decrease of 7.5% compared to RMB 1,397,112,000 for the same period in 2024[19]. - Revenue from medical beauty and wound care products was RMB 573,270,000, down from RMB 631,817,000 in 2024, representing a decline of 9.2%[19]. - Revenue from ophthalmic products decreased to RMB 366,148,000 from RMB 449,659,000, a decline of 18.5%[19]. - The company's product lines showed varied performance, with the ophthalmic products segment declining by 18.57% year-on-year[44]. - The medical beauty market is shifting from rapid expansion to a focus on quality and value, amidst challenges such as regulatory tightening and slowing growth of end institutions[50]. Regulatory and Compliance - The company has complied with all applicable provisions of the Corporate Governance Code under the Hong Kong Listing Rules[104]. - The company has adopted the standard code of conduct for securities trading by directors and supervisors, confirming compliance during the reporting period[105]. - The audit committee held four meetings during the reporting period to review financial statements and internal controls[106]. Future Outlook - The group plans to continue focusing on the four rapidly developing treatment areas: medical beauty, ophthalmology, orthopedics, and surgery, while enhancing research and development and operational efficiency[75]. - The group aims to integrate acquired companies effectively to maximize synergy, improve operational efficiency, and enhance core competitiveness by the second half of 2025[76]. - The group anticipates multiple high-end products, including hydrophobic non-spherical artificial lenses, to be approved within the year, enhancing the overall product line[78].